In community-acquired pneumonia, adding oral clarithromycin to standard care increased early clinical response
- PMID: 38710079
- DOI: 10.7326/J24-0022
In community-acquired pneumonia, adding oral clarithromycin to standard care increased early clinical response
Abstract
Giamarellos-Bourboulis EJ, Siampanos A, Bolanou A, et al. Clarithromycin for early anti-inflammatory responses in community-acquired pneumonia in Greece (ACCESS): a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2024;12:294-304. 38184008.
Conflict of interest statement
Comment on
-
Clarithromycin for early anti-inflammatory responses in community-acquired pneumonia in Greece (ACCESS): a randomised, double-blind, placebo-controlled trial.Lancet Respir Med. 2024 Apr;12(4):294-304. doi: 10.1016/S2213-2600(23)00412-5. Epub 2024 Jan 3. Lancet Respir Med. 2024. PMID: 38184008 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical